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ABSTRACT Antibiotic use has been linked to changes in the population structure
of human pathogens and the clonal expansion of multidrug-resistant (MDR) strains
among healthcare- and community-acquired infections. Here we present a compel-
ling example in a veterinary pathogen, Rhodococcus equi, the causative agent of a
severe pulmonary infection affecting foals worldwide. We show that the erm(46)
gene responsible for emerging macrolide resistance among equine R. equi isolates in
the United States is part of a 6.9-kb transposable element, TnRErm46, actively mobi-
lized by an IS481 family transposase. TnRErm46 is carried on an 87-kb conjugative
plasmid, pRErm46, transferable between R. equi strains at frequencies up to 103.
The erm(46) gene becomes stabilized in R. equi by pRErm46’s apparent ﬁtness neu-
trality and wholesale TnRErm46 transposition onto the host genome. This includes
the conjugally exchangeable pVAPA virulence plasmid, enabling the possibility of
cotransfer of two essential traits for survival in macrolide-treated foals in a single
mating event. Despite its high horizontal transfer potential, phylogenomic analyses
show that erm(46) is paradoxically conﬁned to a speciﬁc R. equi clone, 2287. R. equi
2287 also carries a unique rpoBS531F mutation conferring high-level resistance to ri-
fampin, systematically administered together with macrolides against rhodococcal
pneumonia on equine farms. Our data illustrate that under sustained combination
therapy, several independent “founder” genetic events are concurrently required for
resistance, limiting not only its emergence but also, crucially, horizontal spread, ulti-
mately determining multiresistance clonality.
IMPORTANCE MDR clades arise upon acquisition of resistance traits, but the deter-
minants of their clonal expansion remain largely undeﬁned. Taking advantage of the
unique features of Rhodococcus equi infection control in equine farms, involving the
same dual antibiotic treatment since the 1980s (a macrolide and rifampin), this study
sheds light into the determinants of multiresistance clonality and the importance of
combination therapy in limiting the dissemination of mobile resistance elements.
Clinically effective therapeutic alternatives against R. equi foal pneumonia are cur-
rently lacking, and the identiﬁed macrolide-rifampin MDR clone 2287 has serious im-
plications. Still at early stages of evolution and local spread, R. equi 2287 may dis-
seminate globally, posing a signiﬁcant threat to the equine industry and, also, public
health due to the risk of zoonotic transmission. The characterization of the 2287
clone and its resistance determinants will enable targeted surveillance and control
interventions to tackle the emergence of MDR R. equi.
KEYWORDS ISRe46, MDR clonality, Rhodococcus equi, Rhodococcus equi MDR clone,
Rhodococcus hoagii, Rhodococcus pneumonia, TnRErm46, erm(46), macrolide
resistance, multidrug resistance, pRErm46, rifampin resistance
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Rhodococcus equi is a soil-dwelling facultative intracellular actinobacterium thatcauses pyogranulomatous infections in animals and immunocompromised people
(1–3). While affecting a variety of animal species, R. equi is most commonly isolated
from foals, in which it causes a life-threatening multifocal pneumonic disease with
frequent extrapulmonary involvement (1, 3). Attack rates in farms where the disease is
endemic are typically 10 to 20% or higher, and a larger proportion of foals can be
subclinically affected (4, 5). Equine isolates harbor a host-adapted virulence plasmid of
80 kb designated pVAPA (6–9), required for intramacrophage survival and pathogen-
esis (10). pVAPA is easily lost in the absence of host selection but can be readily
regained, and transmitted between isolates, via conjugal transfer (7, 9, 11–13). Main-
tenance of environmental pools of pVAPA-bearing (i.e., “virulent”) R. equi through
fecal-oral cycling is thought to contribute to farm-level endemicity. Together with two
other host-associated virulence plasmids (porcine pVAPB and ruminant pVAPN) (3, 8, 9,
13), pVAPA plasmids can be found in human isolates (7), consistent with equine settings
being a potential source of human R. equi infection (2).
Control of foal rhodococcosis is challenging due to the lack of an effective vaccine
and relies on antibiotic therapy (4, 14). Treatments are not only applied to clinically
affected animals but also preventatively to presumptive cases identiﬁed by thoracic
ultrasonographic screenings (4, 5, 15–17). Although R. equi is susceptible to a variety of
antimicrobials in vitro (18, 19), many drugs are ineffective in vivo (2, 20). Inconsistent in
vitro susceptibility to some antimicrobials is also observed, with intrinsic resistance
noted for -lactams and quinolones (18, 21–24). Thus, the mainstay of R. equi thera-
peutics on equine farms has been and remains the combination of a macrolide
(erythromycin, clarithromycin, or azithromycin) and rifampin (4).
Since its introduction in the late 1980s (20, 25), the macrolide-rifampin combination
has dramatically reduced foal mortality, until recently with little evidence of resistance
(4, 26). A changing trend was, however, observed in the 2000s, with rates of up to4%
of high-level resistance to both macrolides (MICs, 12 to256 g/ml) and rifampin (MIC,
32 g/ml) reported in the United States (28). Alarmingly, a recent study found up to
40% of foals yielding isolates highly resistant to macrolides and rifampin as a result of
mass antimicrobial treatment (16). While rifampin-only resistance due to rpoB muta-
tions has been reported for R. equi (19, 23, 27–30), including at least two instances
documented during monotherapy in foals (30, 31), macrolide resistance has so far
always been associated with rifampin resistance (16, 28, 32).
We recently identiﬁed a novel erm gene, erm(46), as the cause of the emerging
macrolide resistance among equine R. equi isolates in the United States (32). erm(46)
confers resistance against all macrolides (MIC90 64 to 256 g/ml for azithromycin,
clarithromycin, and erythromycin), lincosamides, and streptogramins B (MLS). In con-
trast to the closely related mycobacterial erm rRNA methylase genes erm(38) and
erm(39), which are part of the intrinsic core resistome, erm(46) was transferable by
mating at frequencies of up to 102 to 103 (32). This was highly concerning not only
due to the risk of rapid spread among equine-associated R. equi organisms but also
because macrolides are critically important antibiotics in human medicine (33) and are
used in the treatment of R. equi infections in people (2).
Here we report the detailed genetic characterization of the erm(46) determinant.
erm(46) is part of a highly mobile transposable element carried on a conjugative
plasmid, pRErm46, from which it colonizes the R. equi genome, including the virulence
plasmid. Despite its high mobility and transfer potential, the erm(46) element is
conﬁned to a speciﬁc R. equi clone, likely as a result of strong coselection due to
concomitant chromosomal rifampin resistance.
RESULTS
R. equi erm(46) is carried on a conjugative plasmid. Whole-genome sequences
(WGS) of 18 MLS-resistant (MLSr) R. equi equine isolates previously used to identify the
erm(46) gene (32) were analyzed to characterize the nature of the transferable element
involved. In most WGS assemblies, erm(46) was found together with an adjacent
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integrase/transposase gene (32) in a unique 6.9-kb contig (Fig. 1A). In one instance
(strain PAM 2275 [see Table S2 in the supplemental material]), the same erm(46)-
containing 6.9-kb fragment was present in an 50- to 62-kb contig (depending on the
assembly) with no homology to any known R. equi genomic DNA (21, 34) and which
contained genes encoding putative conjugation-related type IV secretion system (T4SS)
proteins plus an insertion sequence (IS6100 [see below]) at one of its ends. We
hypothesized this larger contig might be part of a conjugative plasmid harboring the
erm(46) gene within a 6.9-kb transposable element, which then had moved to different
genome locations, explaining its assembly as a separate 6.9-kb contig in most isolates.
We next sought to ascertain the physical presence of erm(46)-associated extrachro-
mosomal DNA in R. equi MLSr plasmid preparations. We used isolates PAM 2287, which
transferred erm(46) at frequencies of up to (1.59 0.52) 103, and PAM 2285, for
which erm(46) transfer was not detected [transfer frequencies for the rest of the isolates
were (7.41 3.86) 105 to (1.13 0.31) 106]. We also used two MLSr transcon-
jugants between PAM 2287 and an MLS-susceptible (MLSs) recipient devoid of any
extrachromosomal DNA (103S–Hygr, a virulence plasmid [pVAPA]-cured genome strain
103S with a chromosomal hygromycin resistance marker), namely, PAM 2350, which
acquired erm(46) but not pVAPA, and PAM 2351, which acquired both erm(46) and
pVAPA (see Materials and Methods).
All erm(46)-positive strains showed the presence of a distinct plasmid band, strik-
ingly, at the very same position as the plasmid DNA from MLSs 103S even if lacking
FIG 1 Integrative elements of the R. equimacrolide resistance plasmid pRErm46. (A) Genetic structure of the 6.9-kb transposon TnRErm46 carrying the macrolide
resistance gene erm(46). The ISRe46 transposase is a novel member of the IS481 family. Its closest homolog is ISRae1 from Rhodococcus aetherivorans (amino
acid identity, 82% [274/333]). TMP is a 25-kDa Gap-like (TauE/SafE superfamily) putative transmembrane protein with a possible role in small-molecule
transport/export. See text and Table S1 for other TnRErm46 components. DR, direct repeats (shaded) at the junction with genomic DNA and adjacent inverted
repeats (IR), which comprise the CTAG sequence targeted by TnRErm46. This sequence provides the TAG stop codons for the ISRe46 transposase on the right
end and for some target genes—whose function is thus not interrupted (e.g., parB on the PAM 2287 pRErm46 plasmid)—on the left end. The left IR provides
the TGA stop codon of the transposon’s distal hypothetical gene (HP). Stop codons are boxed. (B) Genetic structure of pRErm46’s class 1 integron (C1I). The
black rectangles ﬂanking IS6100 represent the 14-bp terminal inverted repeats with the sequence GGCTCTGTTGCAAA. The TnRErm46 insertion within the C1I
cassette gene aadA9, unique to PAM 2287’s pRErm46, is indicated. The aadA9 gene is uninterrupted in most MLSr isolates where pRErm46 was detected,
typically within an 4.4-kb contig covering the intI1-aadA9-qacE-sul1-orf5-tniΔ C1I sequence. PAM 2287’s pRErm46 carries two additional TnRErm46 copies (see
Fig. 3 and Table S2). nt, nucleotide.
Emerging MDR R. equi 2287 Clone ®
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pVAPA (PAM 2350 transconjugant) (Fig. 2A). The identity of the DNA bands was
determined by Southern blotting with speciﬁc probes for pVAPA (internal vapA frag-
ment) and the larger 50-/62-kb contig [internal erm(46) and IS6100 fragments]. The
vapA probe identiﬁed the expected pVAPA band in the equine isolates PAM 2285 and
2287, transconjugant PAM 2351, and control 103S but did not hybridize with the
similarly positioned plasmid DNA band from the erm(46)-positive PAM 2350 transcon-
jugant (Fig. 2B). On the other hand, the erm(46) and IS6100 probes detected a speciﬁc
band at the same position as the vapA signal in isolate PAM 2287 as well as the PAM
2350 and 2351 transconjugants, but not the control 103S plasmid preparation (Fig. 2B).
These data were consistent with erm(46) being present in an extrachromosomal
element of a size similar to that of pVAPA also harboring IS6100, perhaps in several
copies. Indeed, BLASTN searches identiﬁed the insertion sequence in 14 additional MLSr
genome assemblies (but not MLSs genomes) as a discrete 881-bp contig exactly
corresponding to the coding sequence of the 254-residue IS6100 tranposase plus
cognate 14-bp terminal inverted repeats (IR).
FIG 2 Identiﬁcation of erm(46)-associated plasmid DNA (pRErm46). Presence and absence of the
macrolide resistance gene erm(46) or the virulence plasmid is indicated by plus and minus signs,
respectively. The macrolide-susceptible, virulence plasmid-harboring R. equi 103S strain was used as a
control. (A) Agarose gel of plasmid preparations of the indicated representative strains. M, molecular size
marker (Promega 1-kb DNA ladder; top band is 10 kb). The arrowhead indicates the position of the
virulence plasmid and the (pRErm46) resistance plasmid band; both migrate at a theoretical height of
15 kb due to supercoiling. The additional faster-migrating band in the plasmid preparations of PAM
2287 and cognate PAM 2350 transconjugant corresponds to a cryptic plasmid that appears to be
inconsistently transferred. (B) Corresponding Southern blots probed with erm(46), IS6100, and vapA
(pVAPA virulence plasmid) probes (see text for details).
Álvarez-Narváez et al. ®
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Interestingly, no erm(46) or IS6100 probe signal was detected in PAM 2285 plasmid
preparations (Fig. 2B) despite the 6.9-kb erm(46) contig being present in the WGS
assemblies. Since erm(46) transfer was not observed with PAM 2285, we surmised that
in this isolate the 6.9-kb erm(46)-containing putative transposable element might have
jumped onto the chromosome with subsequent loss of the conjugative plasmid
carrying it.
Characterization of pRErm46, a self-transmissible plasmid responsible for
emerging macrolide resistance in R. equi. Single-molecule real-time (SMRT) sequenc-
ing was performed on a plasmid-enriched DNA preparation from the pVAPA-negative
transconjugant PAM 2350. This yielded the complete 5.0-Mb 103S chromosome and a
second scaffold of 87,665 bp comprising the previously identiﬁed 50-/62-kb contig.
This was assumed to correspond to the erm(46)-containing putative conjugative plas-
mid that comigrated with pVAPA (80.6 kb) and was named pRErm46 (Fig. 3).
pRErm46 is a covalently closed DNA molecule as determined with Circlator (35) and
veriﬁed by PCR (Fig. 3). It shares no overall homology with database entries, except for
discrete segments strongly similar to sequences from corynebacterial and (many)
-proteobacterial plasmids (see below). pRErm46 contains 104 coding DNA sequences
(CDSs), of which 92% had homologs in other Actinobacteria, particularly Rhodococcus
spp., suggesting a rhodococcal origin. The GC content (65.09%) is similar to the
average for R. equi genomic DNA (68.7%) (21, 34).
A function could be predicted for 49% of the CDSs. This included products involved
in plasmid maintenance (Fic/Doc-like protein), self-replication (DnaK and DnaB ho-
mologs, putative DNA gyrase/topoisomerase) and partitioning (ParA and duplicated
ParB homologs) (Table S1). Self-transmissibility is mediated by a MOB-P relaxase (36),
MobC-like relaxase-accessory protein (RAP) (37), and T4SS apparatus with a TraG-like
FIG 3 Genetic structure of pRErm46 from R. equi PAM 2287 (reference sequence, GenBank accession no.
KY494640). Highlighted in color are the class 1 integron (yellow) and the TnRErm46 transposon (three
copies, in red; underlined, TnRErm46 insertion shared by all pRErm46 plasmids, presumably the original
site from which secondary transpositions took place). The macrolide resistance erm(46) gene within
TnRErm46 is in black. Excluding the integrative elements, the pRErm46 backbone (in gray) is a conjuga-
tive replicon of 56.7 kb. pRErm46 (PAM 2287) sequence annotation is in Table S1.
Emerging MDR R. equi 2287 Clone ®
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protein and VirB4-like ATPase (38). A LysM-like murein endopeptidase and a secreted
cutinase (Table S1) may help the DNA translocation complex through the bacterial cell
envelope. Actinobacterial cutinases have lipolytic/esterase activity (39) and in myco-
bacteriophages are thought to act as auxiliary LysB lysins aiding the penetration of the
thick mycolic acid layer (40, 41). A cutinase has been shown to promote conjugation of
the R. fascians virulence plasmid pFiD188 (42).
Integrative elements of pRErm46. The additional new sequence in the 87.6-kb
SMRT scaffold revealed a class 1 integron of the “clinical” type (43), with an intI1
integron-integrase gene, passenger gene (aadA9 aminoglucoside adenyltransferase)
(44), and 3= conserved segment (3= CS) comprising qacE (quaternary ammonium
compound efﬂux pump), sulI (drug-resistant sulfonamide target, dihydropteroate syn-
thase) and orf5 sequences (Fig. 1B and Fig. 3). BLASTN searches identiﬁed class 1
integron homologs with virtually the same sequence and core genetic structure in the
plasmids pTET3 from Corynebacterium glutamicum (44) and pLEW279a from Coryne-
bacterium sp. strain L2-79-05 (45) as well as Arthrobacter sp. genomic DNA. Except for
the aadA9 cassette speciﬁc to a subset of homologous sequences, and the 6.9-kb
erm(46) element inserted within the aadA9 gene in pRErm46 from PAM 2350 (Fig. 1; see
also below), entries with identical DNA segments (BLASTN E value, 0.0;99.6% identity)
were abundant among betaproteobacterial plasmids and genomic islands in public
databases.
pRErm46’s class 1 integron carries three directly repeated copies of the IS6 family
insertion sequence IS6100 (Fig. 1B and Fig. 3). First identiﬁed in Mycobacterium fortui-
tum (46), IS6100 is widespread among a diversity of Gram-negative organisms, consis-
tent with an active horizontal exchange of this element between different bacterial
groups (47). In Salmonella, IS6100 is found to be associated with the complex class 1
integron that constitutes the mobilizable multidrug resistance SG1 genomic island (48).
Three IS6100 copies are also found with a similar arrangement in the homologous
regions of the pTET3 (Fig. 1B) and pLEW279a plasmids, suggesting a recent common
origin for the Corynebacteriales mobile class 1 integrons.
Two of pRErm46’s IS6100 copies ﬂank the core integron sequence. At the left, IS6100
is inserted into the intI1 coding sequence (Fig. 1B), which was interpreted in pTET3 as
causing the truncation of the intI1 gene (44). However, analysis of the (identical) region
in pRErm46 reveals that the intI1 open reading frame (ORF) extends into the 3= end of
the convergent IS6100 sequence in the opposite strand and may code for a full-length
integrase. The right IS6100 copy is next to a putative NTP-binding protein/transposon
resolvase pseudogene at the end of orf5 of the 3= CS (Fig. 1B). This is likely the remnant
of a Tn402-like transposon typically carried by “preclinical” class 1 integrons, aka the
tniΔ module (49, 50), which IS6100 presumably functionally replaces.
The third IS6100 copy in pRErm46 is at the end of an additional module that extends
to the right of the integron and harbors a putative tetR-tetA tetracycline efﬂux deter-
minant. An identical IS6100-ﬂanked module (BLASTN E value, 0.0; 99.9% identity) is
found in pTET3 at the opposite (intI1) side of the integron core (Fig. 1B), in pLEW279a,
and in Trueperella (Corynebacterium) pyogenes chromosomal DNA, suggesting that it is
independently mobilizable. IS6100 transposition has been experimentally demon-
strated in Actinobacteria, including Mycobacterium (46, 51), Streptomyces (52), and
Corynebacterium (44). Due to the replicative transposition mechanism of IS6-like ele-
ments, involving cointegrate resolution by homologous recombination (47), directly
repeated ﬂanking IS copies are formed favoring local rearrangements (48, 49). Together
with transposition itself, such recombination-driven rearrangements may explain the
different location of the tetR-tetA module in the otherwise identical class 1 integrons
from pRErm46 and pTET3.
The pRErm46 plasmid sequence of the PAM 2350 transconjugant (originally from the
MLSr equine isolate PAM 2287, which we establish as the reference sequence for
pRErm46; GenBank accession no. KY494640) carries in addition three copies of the
6.9-kb erm(46) element (Fig. 3).
Álvarez-Narváez et al. ®
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TnRErm46 transposon. The TnRErm46 transposon is 6,919 bp in length and com-
prises seven ORFs encoding, in this order, a hypothetical protein, a TetR family
transcriptional regulator, a 25-kDa Gap-like (TauE/SafE superfamily) membrane trans-
porter, an ABC ATPase with a duplicated NTP-binding domain, a putative nucleotide
kinase with an AAA ATPase motif, the erm(46) 23S rRNA methyltransferase, and an IS481
family transposase (Fig. 1A and Table S1). Except for the hypothetical protein, homol-
ogy searches suggest an actinobacterial origin, speciﬁcally rhodococcal. Maximum
identity values of 82 to 89% with its closest homologs (from Nocardia/Rhodococcus
spp.) indicate that the transposase is a novel IS481 member, which we named ISRe46.
IS481 family members are widely distributed in bacteria and may be associated, as
in this case, with cargo genes such as antibiotic resistance determinants and regulators,
constituting self-mobilizable transposons (53). IS481 transposases belong to the Asp-
Asp-Glu (DDE) catalytic motif type and are thought to operate through a copy-paste
mechanism (53). The erm(46) element was conﬁrmed as an ISRe46-driven transposable
unit by the presence in all its multiple insertion sites (see below) of the directly
repeated (DR) hexanucleotide NCTAGN, invariably followed inwards by the inverted
repeat (IR) sequence 5=-TGTTGCGGGTCATGACGTTG-3= (Fig. 1A). Analysis of the inser-
tion sites in the R. equi genome (Fig. 4) indicates that CTAG is the target DNA sequence
for transposition, of which the TAG triplet in the right ﬂanking DR provides the UAG
stop codon for the transposase (Fig. 1A). We named this novel macrolide resistance
transposable element TnRErm46.
One of the three TnRErm46 copies in pRErm46 from PAM 2350/2287 is inserted into
the integron’s passenger gene (aadA9) (Fig. 1). The two other copies are found in a
16.7-kb region between positions 32562 at the 3= end of the parB gene and 49273
before parA in pRErm46’s backbone (Fig. 3 and Table S1). In the left copy the ISRe46
element is a pseudogene due to two frameshift mutations. The second transposition
appears to have involved a duplication of the three left ﬂanking genes from the plasmid
backbone (pRErm46 CDS_0440, pRErm46 CDS_04450, and parB), which as a result are
directly repeated between the two transposon copies (Fig. 3 and Table S1). In both
TnRErm46 copies the TAG of the left NCTAGN DR provides the stop codon for the
FIG 4 TnRErm46 insertions identiﬁed in pRErm46, the R. equi chromosome, and pVAPA virulence plasmid from the 18 MLSr equine isolates
analyzed in this study (cumulative). Numbers correspond to the insertion sites as per the sequence coordinates of the reference R. equi
103S chromosome (GenBank accession no. FN563149) (21), 103S pVAPA (pVAPA1037, GenBank accession no. AM947677) (8), and PAM
2287 pRErm46 (GenBank accession KY494640 [this study]). In parentheses is the number of instances in which a particular insertion was
detected. In pRErm46, 16/16 corresponds to 100% of isolates in which pRErm46 sequences were detected in the genome assemblies. One
of the 20 chromosomal insertion sites was in a resistant clone-speciﬁc region. The accessory genome accounts for 20% of an R. equi
isolate’s gene content (34).
Emerging MDR R. equi 2287 Clone ®
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repeated parB1 and parB2 genes (Fig. 3). Interestingly, these transposition events took
place at the parA/B plasmid partitioning module, previously identiﬁed in the R. equi
virulence plasmids and related rhodococcal replicons as a hot spot for integration of
foreign DNA (8, 13).
Pervasive genomic colonization by TnRErm46. The multiple copies of TnRErm46
in pRErm46 (PAM 2350/2287) suggested that it is an actively transposable element. To
gain insight into this issue, we searched for the TnRErm46 sequences in the WGS
assemblies of the 18 MLSr isolates. Contigs with 100% matching nucleotide sequences
to either of the TnRErm46 ends were aligned with BLASTN against the R. equi chromo-
some and the reference sequences of the equine-type virulence plasmid pVAPA1037
(GenBank accession number AM947677) (8) and resistance plasmid pRErm46. To pin-
point the chromosomal insertions, we used a draft SMRT sequence of PAM 2287
(reference isolate of the MLSr clone; see below) and the reference (complete) R. equi
103S genome sequence (21) for coordinate assignment.
Figure 4 shows the TnRErm46 insertions identiﬁed for all the MLSr clinical isolates.
Transposition into the bacterial chromosome was detected in all but one of the isolates
(PAM 2275), up to ﬁve times in some cases. A total of 35 insertions at 20 different
chromosomal sites were identiﬁed. In addition, TnRErm46 was found in the pVAPA
virulence plasmid in four isolates (one copy in PAM 2283, 2284, and 2287 and four
copies in PAM 2286). Except nucleotide position 55131 shared by pVAPA2286 and
pVAPA2287, the element was inserted at different pVAPA locations (Fig. 4 and Ta-
ble S2). Again, it is noteworthy that four of the seven pVAPA insertions were in the
plamid’s replication/partitioning module. This region was previously identiﬁed in
pVAPA and related circular rhodococcal plasmids as the integration site for the hori-
zontal gene transfer (HGT) DNA which constitutes the plasmid-speciﬁc, niche-adaptive
variable region (VR) (8, 13). In pVAPA, the VR corresponds to the horizontally acquired
vap pathogenicity island (PAI), which itself provided one of the insertion sites for
TnRErm46. Consistent with the clinical source of the bacteria and the requirement of a
functional virulence plasmid/vap PAI for host colonization (54, 55), none of the trans-
poson insertions, including the one within the theoretical boundaries of the vap PAI
(Fig. 4) (at nt position 59315 targeting the stop codon of a pseudogene), are likely to
affect the expression of critical pVAPA genes, speciﬁcally virulence-associated determi-
nants.
Finally, all pRErm46 plasmids harbored at least two TnRErm46 copies in a combina-
tion of common and unique locations. The only exception is PAM 2275, with a single
transposon insertion at position 32567. This speciﬁc insertion is shared by all pRErm46
plasmids analyzed (Table S2), suggesting that it corresponds to the original transposi-
tional event through which the pre-pRErm46 replicon acquired the erm(46) determi-
nant (Fig. 5). Of note, the TnRErm46 insertion within the aadA9 gene found in pRErm46
from PAM 2350/2287 (Fig. 1 and 3) is unique to this isolate. However, TnRErm46 was
found within the integron’s 3= CS in three other isolates, targeting sul1 (once) and orf5
(three different sites) (Table S2). Of a total of 11 identiﬁed insertion sites in the pRErm46
plasmids, ﬁve were within the class 1 integron (Fig. 4), consistent with bacterial
integrons serving as ﬂexible recruitment platforms for resistance-encoding DNA and
transposable elements (43).
For three isolates, PAM 2280, 2285, and 2289, class 1 integron sequences were not
found in the WGS assemblies despite the fact that the isolates carried the TnRErm46
element. However, pRErm46 (including the class 1 integron) was detected by PCR and
BLASTN mapping of the TnRErm46 insertion sites in PAM 2289 and by PCR in PAM 2280
(Table S2), suggesting that perhaps the resistance plasmid was present in only a small
fraction of these isolates’ populations. PAM 2285, in contrast, appears to have actually
lost the pRErm46 plasmid and to carry TnRErm46 only on the chromosome (Table S2).
This would explain the inability of this isolate to transfer the erm(46) element/MLSr
phenotype in mating experiments.
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Overall, the data reveal a pattern of active, widespread dissemination of TnRErm46
across the host R. equi genome. This includes the extrachromosomal replicons, i.e., the
pRErm46 resistance plasmid and the pVAPA virulence plasmid, both of which are
conjugally transferable. Conjointly, all these mechanisms ensure the stable mainte-
nance of the newly acquired resistance element in R. equi (Fig. 5).
Cotransfer of macrolide resistance and virulence determinants. In mating ex-
periments with PAM 2287, 74% of the erm(46)-positive (erythromycin resistant [Ermr])
103S– transconjugants had also acquired the virulence plasmid. To further document
that pVAPA can transfer erm(46), we examined one such erm(46)/pVAPA-positive
transconjugant, PAM 2351 (see above), by SMRT sequencing. The sequence analyses
conﬁrmed that pVAPA from PAM 2351 carried TnRErm46 inserted at position 55132 (3=
end of parB) as in the donor PAM 2287, consistent with the transposon having been
conjugally transferred in situ within pVAPA. Notably, this insertion was accompanied by
three additional copies of TnRErm46 in the virulence plasmid (Fig. S1). These data
FIG 5 Fate of TnRErm46 macrolide resistance transposon upon acquisition by an equine R. equi isolate. (Top left)
Formation of pRErm46 via transposition of TnRErm46 into a Corynebacteriales conjugative replicon; (bottom left)
pRErm46 is conjugally transferred from a hypothetical Corynebacteriales donor to R. equi. The highly mobile
TnRErm46 element can transpose from its original location (position 32567, common to all R. equi pRErm46
plasmids [see text and Fig. 4]) to other genome sites, resulting in several possible scenarios, as follows. (a)
transposition within pRErm46 and onto the chromosome but not the virulence plasmid; (b) same as in panel a plus
transposition to pVAPA; (c) same as in panel b, with subsequent loss of pRErm46; (d) same as in panel a, with
subsequent loss of pRErm46. The pervasive colonization of the R. equi genome by TnRErm46 leads to stabilization
of macrolide resistance in the host strain, while potential lateral transfer of TnRErm46 may occur via pRErm46, the
pVAPA virulence plasmid, or both (solid red arrows). Options a, b, and d, in addition to TnRErm46 remaining in
single copy at its original location in pRErm46 (isolate PAM 2275), have been veriﬁed in the 18 MLSr equine isolates
analyzed (see Table S2).
Emerging MDR R. equi 2287 Clone ®
September/October 2019 Volume 10 Issue 5 e02260-19 mbio.asm.org 9
 o
n
 N
ovem
ber 12, 2019 at UNIVERSITY O
F EDINBURG
H
http://m
bio.asm
.org/
D
ow
nloaded from
 
conﬁrm that the TnRErm46 element can actively transpose within a relatively short time
frame. They also conﬁrm that the virulence plasmid, essential for host colonization, may
serve itself as a spread vector for the macrolide resistance determinant erm(46).
Clonal spread of pRErm46/TnRErm46. R. equi isolates from equine settings or
clinical specimens are genotypically diverse not only at a global population level (34)
but also within the same farm (56) or even the same animal (56, 57). The various
conjugal exchange routes for TnRErm46, via either pRErm46, pVAPA, or both, hence
would predict a situation of rapid spread across a diversity of R. equi strains. To
investigate this, we performed a phylogenomic analysis of the 18 erm(46)-positive
isolates available for this study and 27 control MLSs strains. The resistant isolates were
all obtained from different US states over a period of a decade (34) while the control
susceptible set comprised six coetaneous random equine isolates from the same
geographic areas (Table S2) plus 22 strains representative of the global genomic
diversity of R. equi (34) (Table S3). The latter included the type strain DSM 20307
(ATCC 6939) and 103S ( DSM 104936 NCTC 13926) (21) used as the reference
genome.
Figure 6 shows a core genome phylogeny based on a Parsnp alignment (58). While
the control equine isolates were randomly distributed across the R. equi population
structure, all 18 TnRErm46-harboring isolates clustered together within a distinct clade
at the top of the tree. In a context where all members of the R. equi species radiate at
a short genetic distance from each other (34), the macrolide-resistant group differed
from the nearest control isolates by 25,000 to 27,000 single nucleotide polymor-
phisms (SNPs) (over 3,800 core genes/4.2 Mbp). In contrast, the resistant group
differed only by an average of 60 (43 to 102) SNPs in pairwise comparisons, indicating
that it corresponds to a recently emerged R. equi clone (Fig. S2).
The erm(46)-positive R. equi bacteria also exhibited rifampin resistance (Rifr) (MIC90
32 g/ml, versus 0.25 g/ml for MLSs equine isolates) (32, 59). Analysis of the rpoB
sequences revealed in all of them the same missense mutation at codon 443 resulting
in a Ser¡Phe substitution. None of the susceptible isolates carried any rpoB mutation.
The location corresponds to Escherichia coli RpoB position 531 within rifampin
resistance-determining region 1 (RRDR-1; residues 507 to 533), where the same sub-
stitution is known to cause the Rifr phenotype (60). Different RRDR-1 Rifr mutations
have been previously reported for R. equi, including Ser531Leu and Ser531Trp (E. coli
numbering), associated with MICs of 8 g/ml and 64 g/ml, respectively (19, 28–30).
Like Ser531Trp, the Ser531Phe rpoB mutation, which had never been described before
for R. equi, introduces a large aromatic side chain at position 531 and is also associated
with a relatively high level of rifampin resistance.
Our data thus indicate that the emerging macrolide resistance detected among R.
equi equine isolates in the United States is due to a speciﬁc clone that acquired the
TnRErm46 element and is characterized by a distinct Rifr mutation.
Fitness neutrality of pRErm46. We ﬁnally considered to what extent the clonal
spread of erm(46)-mediated macrolide resistance could have been inﬂuenced by a
speciﬁc adaptation of the pRErm46 plasmid to the host strain. To explore this, we tested
whether pRErm46 acquisition entailed any ﬁtness cost upon transfer to the 103S strain,
which belongs to an early clonal bifurcation of R. equi (lineage I) different from that of
the resistant clone (lineage II) (34). The analyses were performed with low-passage-
number PAM 2350 cultures stored after conjugation to minimize the potential impact
of adaptive plasmid cost amelioration (61, 62).
No signiﬁcant differences in exponential growth rate () or maximum growth (A)
were observed between pRErm46-bearing PAM 2350 and the plasmid-devoid 103S
recipient in either complex media (brain heart infusion [BHI] and Luria-Bertani [LB]
broth) or chemically deﬁned medium (Fig. 7A and B). The two strains also showed no
signiﬁcant differences in competitive ability in vitro in the absence of antibiotic pressure
(Fig. 7C). Thus, pRErm46 does not seem to impose signiﬁcant ﬁtness costs upon transfer
to a different R. equi genomic background.
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DISCUSSION
The rise of antimicrobial resistance (AMR) among leading human pathogens is often
associated with speciﬁc clonal complexes that become globally disseminated (63).
While phylogenomic studies have clearly linked the emergence of such successful
clades to founder genetic events involved in the acquisition of resistance (63–68), the
drivers of the clonal expansion remain largely speculative. Our study captured one such
founder event at the early stages of its evolution in a major animal pathogen, R. equi,
providing valuable insight into the determinants of AMR clonality.
FIG 6 Clonal spread of TnRErm46-mediated macrolide resistance. Phylogenetic tree of 46 R. equi isolates
based on core genome SNP analysis using Parsnp (58). The genomes analyzed are from 18 MLSr and 6
control MLSs equine isolates from different U.S. states (highlighted in red and blue, respectively) plus 22
isolates representative of the genomic diversity of the species, including the reference genome from
strain 103S (DSM 104936 NCTC 13926; GenBank accession no. FN563149 [21]) and the type strain DSM
20307 ( ATCC 6939; GenBank accession no. LWTX00000000 [34]). Numbers in the nodes indicate
bootstrap values for 1,000 replicates. The tree graph was constructed with FigTree (http://tree.bio.ed.ac
.uk/software/ﬁgtree/). See also Fig. S2.
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We show that the emerging erm(46)-mediated MLSr detected among equine R. equi
isolates in the United States (32) is due to a speciﬁc clone that carries a mobile element
and a chromosomal mutation conferring dual resistance to, respectively, macrolides
and rifampin, the mainstay of antibiotic therapy against foal rhodococcosis since the
1980s (20, 26). Diverse Rifr rpoBmutations have been previously reported for R. equi (19,
28–30), indicating that such chromosomal mutations occur regularly and alone are
insufﬁcient to support the clonal expansion of a speciﬁc strain. It seems likely that the
conjugal acquisition of the hitherto undescribed pRErm46 plasmid and cognate
erm(46)-carrying TnRErm46 transposon has been the decisive trigger in the emergence
of the R. equi multidrug-resistant (MDR) clone.
Mobile resistance elements have been traced to the origin of major MDR clonal
complexes (63). The elements often become stabilized in the host genome and evolve
with the clone, with little evidence of active, short-term mobilization or lateral trans-
ferability. Examples include SCCmec in methicillin-resistant Staphylococcus aureus
(MRSA) (69), the AbaR genomic island/composite transposon in Acinetobacter bauman-
nii clonal complex GC1 (68, 70), and the SG1 MDR island in Salmonella enterica serovar
Typhimurium DT104 (71). On other occasions, exempliﬁed by the plasmid-borne genes
blaKPC in Klebsiella pneumoniae clonal group 258 and blaCTX-M-15 in Escherichia coli
ST131 (66, 67, 72), the mobile resistance element promotes the clonal ampliﬁcation
while at the same time it exploits the dominance of their host clone to disseminate and
drive the expansion of other diverse bacterial lineages/species (63).
In our case, the erm(46) macrolide resistance determinant is restricted to a speciﬁc
R. equi clone yet its vehicle is a highly mobile, potentially actively transferable element.
Moreover, transferability is maximized through co-option of the conjugative machinery
of the pVAPA virulence plasmid (Fig. 5), physically linking two essential traits required
for the colonization of a macrolide-rifampin-treated equine host. Furthermore, evi-
dence indicates that pVAPA plasmids are actively exchanged between R. equi lineages
FIG 7 Acquisition of pRErm46 is ﬁtness neutral. pRErm46 was conjugally transferred from the MDR clone (PAM 2287) to a different
chromosomal lineage (strain 103S [see Fig. 6]). PAM 2350, pRErm46 103S transconjugant. PAM 2266, isogenic recipient 103S bacteria
without pRErm46 (virulence plasmid-cured 103S with a chromosomal Hygr marker for counterselection of pRErm46 donor strain in
mating experiments). (A) Growth curves in rich complex medium (LB or BHI) and chemically deﬁned medium (mREMM [see Materials
and Methods]). (B) Growth rate () and maximum growth (A) values from experiments in panel A. (C) Competitive growth experiments.
No signiﬁcant differences between the isogenic pair of bacteria with and without pRErm46 were observed (all P values  0.7, one-way
ANOVA followed by Šidák post hoc comparison).
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(9, 34), facilitated by alternation of spontaneous plasmid loss in the absence of host
pressure (7, 11) and high-frequency conjugative reacquisition (12). While these features
theoretically anticipate the rapid spread of TnRErm46 across the array R. equi popula-
tions typically colonizing the equine farm environment (56, 57), the MDR clone (dubbed
2287 after the isolate from which the pRErm46 reference sequence derives) has been
circulating since at least 2002 (Table S2), until now with no apparent TnRErm46 spillover
to other R. equi lineages.
How can the paradoxical clonal conﬁnement of the otherwise highly mobile
TnRErm46 element/pRErm46 plasmid be explained? Our data appear to exclude ﬁtness
constraints, because acquisition of the pRErm46 plasmid does not seem to entail
signiﬁcant costs in a different R. equi genomic background. In addition, any ﬁtness cost
would be largely compensated in antibiotic-treated animals in which resistance confers
a selective advantage (73). We suggest that clonality is primarily determined by the
inability of pRErm46/TnRErm46 to ensure alone the evolutionary viability of the host R.
equi bacteria in the absence of a chromosomal rpoB mutation under combined
macrolide-rifampin pressure. Under these conditions, the probability of concurrent
acquisition of the pRErm46 plasmid and a Rifr mutation reoccurring de novo would be
vanishingly small (as low as 1010/–14, considering individual in vitro frequencies of,
respectively, 102/–6 [most often 105] and 108 [30; our unpublished observa-
tions]) compared to the likelihood of the existing R. equi 2287 clone spreading through
horse trading or cross-exposure at racecourses.
Human-pathogenic MDR clones typically begin as localized expansions and
rapidly—within a few years—disseminate pandemically and diversify in clonal com-
plexes (63–66, 72). Despite the high prevalence of R. equi in horse breeding countries,
after more than 15 years R. equi 2287 still appears to be at the initial stages of local
dissemination. This apparently slow expansion arguably stems from the fewer oppor-
tunities for spread afforded by the signiﬁcantly smaller size and restricted geographical
mobility of the equine versus human populations. Bar the diversity of TnRErm46
insertion sites, R. equi 2287 isolates also show very limited genetic variability, presum-
ably a reﬂection of the ecological stability of the equine niche to which the clone is
restricted. We predict that, over time, R. equi 2287 will probably become globally
disseminated, accumulate additional resistance mechanisms (63, 64, 68, 72, 74), and
eventually enter a path of fast genome evolution fueled by the continued transposition
and ampliﬁcation of the ISRe46 element, as observed in Bordetella pertussis with the
homologous insertion sequence IS481 (75). pRErm46 (or TnRErm46 carried by other
mobile elements, e.g., bacteriophages [41]) is also likely to be horizontally transferred
to other R. equi strains or equine-associated microbiota.
In addition to being a veterinary proxy of the nosocomial setting in terms of
intensive antimicrobial use and close-contact transmission, the particularities of R. equi
antibiotic control in equine farms, based on the same drug combination for decades,
offer a unique “controlled” scenario that helps illuminating the factors underlying AMR
clonal spread. Our ﬁndings illustrate that under sustained combination therapy, AMR
requires the co-occurrence of independent founder events, thereby effectively reduc-
ing the likelihood of resistance emergence and expansion to a speciﬁc bacterial clone.
They also highlight the impact of ecological bottlenecks imposed by antimicrobial use
in shaping the population dynamics of pathogens (74) and the potential effectiveness
of combination therapies in limiting not only the emergence (76, 77) but also, critically,
the spread of resistance—even if conferred by highly mobile elements.
While consubstantial to and underpinning AMR, clonal spread provides at the same
time a predictable framework to develop control strategies. The pRErm46 plasmid and
TnRErm46 element here reported, together with the identiﬁcation of the Rifr 2287
lineage harboring these, lay the foundations for the effective tracking and control of
emerging macrolide-rifampin multiresistance among equine R. equi isolates and its
potential zoonotic transmission to humans.
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MATERIALS AND METHODS
Bacteria, culture conditions, and reagents. The 18 MLSr and 6 control MLSs isolates analyzed in this
study were selected from a collection of R. equi cultures obtained from tracheobronchial aspirates or
postmortem tissue of infected foals from different U.S. states between 2002 and 2013 (32) (Table S2).
WGS shotgun assemblies thereof were previously used in the identiﬁcation of the erm(46) gene (32). WGS
assemblies from 22 additional control isolates representative of the global diversity of R. equi have been
previously described (34). The presence of the virulence plasmid and pRErm46 plasmid/TnRErm46
element was routinely checked by PCR using speciﬁc oligonucleotide primers (Table S4). R. equi was
grown in brain heart infusion medium (BHI; Difco-BD) at 30°C unless otherwise stated, with orbital
shaking (200 rpm) for ﬂuid cultures. Bacteriological agar (Oxoid) was used at 1.6% (wt/vol) for plate
cultures. Antibiotic supplements were added as required after autoclaving. Chemicals and oligonucleo-
tide primers were purchased from Sigma-Aldrich unless otherwise stated.
Conjugal transfer of pRErm46. Mating experiments were carried out as described by Anastasi et al.
(32) using a 1:1 donor to recipient ratio. A virulence plasmid (pVAPA)-cured derivative of the genome
strain 103S (21) with a chromosomal hygromycin resistance marker was used as a recipient for
counterselection of the wild-type donor isolate (designated 103S– Hygr; internal collection no. PAM
2266). After incubation at 30°C for 72 h, transconjugants were selected on BHI agar supplemented with
200 g/ml of hygromycin B and 10 g/ml of erythromycin. pRErm46 transfer was conﬁrmed by PCR
analysis of at least 30 Hygr Ermr colonies per experiment using ad hoc primers (Table S4). Transfer
frequencies were calculated by dividing the number of Hygr Ermr bacteria by the total number of
recipient bacteria.
DNA techniques. Plasmid DNA for Southern blotting was extracted from exponential BHI cultures
(optical density at 600 nm [OD600] 1.0) using an alkaline precipitation protocol as previously described
(7). Total and plasmid-enriched DNA for sequencing was obtained using the GenElute bacterial genomic
DNA kit (Sigma-Aldrich) and QIAﬁlter midikit (Qiagen), respectively. Total DNA for routine PCR tests was
prepared by heating single bacterial colonies at 100°C in 100 l of ultrapure water and centrifugation for
90 s at 16,000  g. PCR was performed as previously described (13). Oligonucleotide primers used are
shown in Table S4. For Southern blotting, plasmid preparations were electrophoresed in 0.5% agarose
and transferred to positively charged nylon membranes (Roche) after treatment of the gels with
denaturing solution (1.5 M NaCl 0.5 N NaOH) for 30 min and neutralizing solution (1.5 M NaCl, 0.5 M
Tris-HCl pH 7.5) twice for 20 min. Probes consisted of digoxigenin-labeled internal fragments of the genes
of interest [vapA, erm(46), and IS6100 transposase] generated with the PCR DIG probe synthesis kit
(Roche) using suitable oligonucleotide primers (Table S4). Membranes were hybridized at high stringency
and developed according to the manufacturer’s instructions. Hybridized membranes were stripped with
0.2 N NaOH–0.1% SDS at 45°C for 30 min before reprobing.
DNA sequencing and analysis. Illumina shotgun libraries of 24 R. equi equine clinical isolates (18
MLSr and six MLSs) obtained by Anastasi et al. (32) were used in this study. Genomes were assembled de
novo as previously described (34) or using a modiﬁed protocol with Cutadapt software for adapter
removal (78) and QUAST for quality assessment (79). SMRT PacBio genome sequencing of PAM 2350 and
2351 transconjugants was performed by BGI Genomics (Hong Kong) and BaseClear sequencing services
(The Netherlands), respectively. Minimap and Miniasm (de novo assembler) software was used for
mapping and de novo assembling single SMRT data (80), and Racon for consensus calling (81). Circlator
(35) was run with error corrected reads from the Canu v1.3 error correction module for assembly
circularization to obtain an accurate linear representation of circular sequences (82). Annotation of the
assemblies was performed using Prokka V1.11 (83) and InterProScan v5.17. pRErm46 annotations were
manually inspected and curated based on Blast analysis. Whole-genome phylogenies were inferred using
Parsnp in the Harvest suite, designed for SNP analysis between closely related species/strains (97%
average nucleotide identity [ANI]) (58). Parsnp uses FastTree 2 (84) to build approximate maximum
likelihood trees from core-genome SNPs.
Fitness assays. Effects on bacterial ﬁtness were investigated by monitoring the growth and
competitive ability in two complex media (BHI and LB) and in chemically deﬁned medium (modiﬁed R.
equi minimal medium [mREMM]) (34) supplemented with two rapidly metabolizable carbon sources
(50 mM sodium lactate and 25 mM sodium acetate), as previously described (85). Brieﬂy, exponential-
phase BHI cultures were washed in phosphate-buffered saline (PBS), resuspended in fresh medium to
give an OD600 of 0.05, and triplicate 400-l aliquots of the suspension transferred to 48-well plates.
Bacterial growth was monitored at 30°C every 30 min using an automated plate reader (Optima
apparatus, BMG). The maximum growth rate () and maximum bacterial cell density (A) were estimated
from spline-ﬁts of OD600 values using the Groﬁt package in R (86) as previously described (85). Pairwise
competition experiments were carried out as described above with a bacterial inoculum consisting of a
1:1 mix of the two test bacteria. At speciﬁc time points, cultures were sampled and appropriate dilutions
spread on LB agar supplemented with suitable antibiotics for differential counting. The competitive index
was calculated using the formula CI (test/reference log CFU ratio at t n)/(test/reference log CFU ratio
at t 0) (13, 85).
Statistics. Growth parameters were analyzed using one-way analysis of variance (ANOVA) followed
by Šidák post hoc multiple-comparison tests unless otherwise stated. Onesample Student ttests were
used to determine if competition index (CI) values differed signiﬁcantly from 1 (the theoretical CI value
if the ratio of the competing strains remains the same with respect to that at time zero). Statistical
analyses were performed using Prism 8.0.2 software (GraphPad Software Inc., San Diego, CA).
Accession number(s). The reference sequence of the pRErm46 plasmid from R. equi PAM 2287 has
been deposited at GenBank under accession no. KY494640. R. equi WGS assemblies used in this study
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that were not previously reported have been deposited under accession no. MULU00000000,
MUMB00000000, MUMA00000000, MULW00000000, MULT00000000, MULY00000000, MULZ00000000,
MULX00000000, MUXK00000000, MVDS00000000, MVDT00000000, MVDU00000000, MVDV00000000,
MVDQ00000000, MVDR00000000, MUXJ00000000.
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